Holen Sie sich die Stockscreener-App
5.03
0.00%
0.00
Handel nachbörslich:
5.03
Lisata Therapeutics Inc Aktie (LSTA) Neueste Nachrichten
Lisata Therapeutics : Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K) - marketscreener.com
Lisata Therapeutics agrees to $5 per share acquisition by Kuva Labs - Investing.com Nigeria
Lisata Therapeutics to Be Acquired by Kuva Labs for $5.00 Per Share Plus Potential $1.00 CVR in 2026 Merger Deal - Minichart
Market movers: Hims & Hers, Lisata Therapeutics, Live Nation Entertainment... - Proactive financial news
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances - Yahoo Finance
Lisata Therapeutics to Be Acquired by Kuva Labs - TipRanks
Lisata Therapeutics to Be Acquired by Kuva Labs in $5.00-Per-Share Tender Offer Plus $1.00 CVR - TradingView
Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Lisata Therapeutics Hits New 52-Week High of $5.06 - Markets Mojo
Lisata Therapeutics Agrees To Be Taken Private By Kuva Labs - Nasdaq
Lisata Therapeutics (LSTA) to be Acquired by Kuva Labs in $5.00 per Share Deal - GuruFocus
Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc. - TradingView
Lisata Therapeutics Announces Acquisition by Kuva Labs Inc. with $5.00 Cash Offer per Share - Quiver Quantitative
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. - GlobeNewswire
Lisata Extends Kuva Labs Acquisition Term Sheet Timeline - TipRanks
Lisata Extends Kuva Tender Offer Term Sheet to March 7 as Acquisition Talks Continue - TradingView
Will Lisata Therapeutics Inc. stock go up in YEARJuly 2025 Analyst Calls & Technical Pattern Based Buy Signals - mfd.ru
LSTA SEC FilingsLisata Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lisata Therapeutics (LSTA) Price Target Increased by 19.30% to 11.56 - Nasdaq
LSTA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Why is Lisata Therapeutics Inc. stock going downAnalyst Downgrade & Precise Entry and Exit Recommendations - mfd.ru
What is the long term forecast for Lisata Therapeutics Inc. stockJuly 2025 Decliners & Comprehensive Market Scan Insights - mfd.ru
Can Lisata Therapeutics Inc. keep up with sector leadersTrade Risk Summary & Free Accurate Trade Setup Notifications - mfd.ru
LSTA PE Ratio & Valuation, Is LSTA Overvalued - Intellectia AI
Will Lisata Therapeutics Inc. (8NE) stock benefit from sector leadershipMarket Risk Summary & Accurate Intraday Trade Tips - mfd.ru
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareho - GuruFocus
Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s Investigations - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Swing Trade: Can SILA withstand a market correctionTrade Volume Report & Technical Pattern Alert System - baoquankhu1.vn
Signal Recap: Will Lisata Therapeutics Inc stock benefit from M ARisk Management & Technical Confirmation Trade Alerts - baoquankhu1.vn
What Does the Market Think About Lisata Therapeutics Inc? - Benzinga
Halper Sadeh LLC Investigates Potential Violations by Multiple Companies - intellectia.ai
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - Finviz
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA - Finansavisen
Lisata regains full rights to certepetide in Greater China region By Investing.com - Investing.com Canada
Deal Watch: Kuva Labs To Go Public Via Merger With Licensing Partner Lisata - Citeline News & Insights
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement By Investing.com - Investing.com South Africa
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement - Investing.com Nigeria
Lisata regains full rights to certepetide in Greater China region - Investing.com
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - marketscreener.com
Lisata Therapeutics (LSTA) Ends Licensing Agreement with Qilu Ph - GuruFocus
Lisata Therapeutics ends Qilu certepetide collaboration deal - TipRanks
Lisata regains China rights to pancreatic cancer drug - Proactive financial news
Lisata Therapeutics and Qilu Pharmaceutical Terminate License Agreement - TradingView
Cancer drug rights shift: Lisata takes back certepetide in China - stocktitan.net
Lisata shares nearly double on buyout offer: Here are the details - MSN
Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals - RTTNews
Lisata Therapeutics to be acquired by Kuva Labs in $4.00-per-share cash deal - MSN
Lisata Therapeutics surges on Kuva Labs takeover proposal carrying hefty premium - MSN
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Kuva Labs to acquire Lisata Therapeutics for $4 per share By Investing.com - Investing.com Nigeria
Lisata Therapeutics Agrees to All-Cash Acquisition by Kuva - The Globe and Mail
How The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation Outlook - Yahoo Finance
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):